Journal of Cardiac Failure
Volume 15, Issue 9 , Pages 770-774 , November 2009

Antibodies to Oxidized LDL as Predictors of Morbidity and Mortality in Patients With Chronic Heart Failure

  • Gideon Charach, MD

      Affiliations

    • Department of Cardiology, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel
    • Internal Medicine “C”, Tel Aviv, Israel, affiliated to the Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel
    • Corresponding Author InformationCorrespondence to: Gideon Charach, MD, The Department of Cardiology, Tel Aviv Sourasky Medical Center, 6 Weizman Street, Tel Aviv, 64239 Israel. Tel: +972-524-266851; Fax: +972-3-6974990.
    • ,
  • Jacob George, MD

      Affiliations

    • Department of Cardiology, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel
    • ,
  • Arnon Afek, MD, MHA

      Affiliations

    • Lipid Unit, Tel Aviv, Israel, affiliated to the Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel
    • ,
  • Dov Wexler, MD

      Affiliations

    • Department of Cardiology, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel
    • ,
  • David Sheps, MD

      Affiliations

    • Department of Cardiology, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel
    • ,
  • Gad Keren, MD

      Affiliations

    • Department of Cardiology, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel
    • ,
  • Ardon Rubinstein, MD

      Affiliations

    • Lipid Unit, Tel Aviv, Israel, affiliated to the Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel

Received 22 November 2008 ,Revised 4 May 2009 ,Accepted 7 May 2009.

References 

  1. Griendling KK, FitzGerald GA. Oxidative stress and cardiovascular injury: Part II. Animal and human studies. Circulation. 2003;108:2034–2040
  2. McMurray J, Chopra M, Abdullah I, Smith WE, Dargie HJ. Evidence of oxidative stress in chronic heart failure in humans. Eur Heart J. 1993;14:1493–1498
  3. Ellis GR, Anderson RA, Lang D, Blackman DJ, Morris RH, Morris-Thurgood J, et al. Neutrophil superoxide anion-generating capacity, endothelial function and oxidative stress in chronic heart failure: effects of short and long-term vitamin C therapy. J Am Coll Cardiol. 2000;36:1474–1482
  4. Myers CE, McGuire WP, Liss RH, Ifrim I, Grotzinger K, Young RC. Adriamycin: the role of lipid peroxidation in cardiac toxicity and tumour response. Science. 1977;197:165–167
  5. Singal PK, Kapur N, Dhillon KS, Beamish RE, Dhalla AK. Role of free radicals in catecholamine-induced cardiomyopathy. Can J Physiol Pharmacol. 1982;60:1390–1397
  6. Dhalla AK, Hill MF, Singal PK. Role of oxidative stress in transition of hypertrophy to heart failure. J Am Coll Cardiol. 1996;28:506–514
  7. Siveski-Iliskovic N, Hill M, Chow DA, Singal PK. Probucol protects against Adriamycin cardiomyopathy without interfering with its antitumor effect. Circulation. 1995;91:10–15
  8. Sobotka PA, Brottman MD, Weitz Z, Birnbaum AJ, Skosey JL, Zarling EJ. Elevated breath pentane in heart failure reduced by free radical scavenge. Free Radic Biol Med. 1993;14:643–647
  9. Mallat Z, Philip I, Lebret M, Chatel D, Maclouf J, Tedgui A. Elevated levels of 8-iso-prostaglandin F2 alpha in pericardial fluid of patients with heart failure: a potential role for in vivo oxidant stress in ventricular dilatation and progression to heart failure. Circulation. 1998;97:1536–1539
  10. Boullier A, Bird DA, Chang MK, Dennis EA, Friedman P, Gillotre-Taylor K, et al. Scavenger receptors, oxidized LDL, and atherosclerosis. Ann N Y Acad Sci. 2001;947:214–222
  11. Holvoet P, Vanhaecke J, Janssens S, Van de Werf F, Collen D. Oxidized LDL and malondialdehyde-modified LDL in patients with acute coronary syndromes and stable coronary artery disease. Circulation. 1998;98:1487–1494
  12. Holvoet P, Mertens A, Verhamme P, Bogaerts K, Beyens G, Verhaeghe R, et al. Circulating oxidized LDL is a useful marker for identifying patients with coronary artery disease. Arterioscler Thromb Vasc Biol. 2001;21:844–848
  13. Tsutsui T, Tsutamoto T, Wada A, Maeda K, Mabuchi N, Hayashi M, et al. Plasma oxidized low-density lipoprotein as a prognostic predictor in patients with chronic congestive heart failure. J Am Coll Cardiol. 2002;39:957–962
  14. Steinerova A, Racek J, Stozicky F, Zima T, Fialova L, Lapin A. Antibodies against oxidized LDL—theory and clinical use. Physiol Res. 2001;50:131–141
  15. Salonen JT, Yla-Herttuala S, Yamamoto R, Butler S, Korpela H, Salonen R, et al. Autoantibodies against oxidized LDL and progression of carotid atherosclerosis. Lancet. 1992;339:883–887
  16. Lehtimaki T, Lehtinen S, Solakivi T, Nikkila M, Jaakkola O, Jokela H, et al. Autoantibodies against low density lipoprotein in patients with angiographically verified coronary artery disease. Arterioscler Thromb Vasc Biol. 1999;19:23–27
  17. Puurunen M, Manttari M, Manninen V, Tenkanen L, Alfthan G, Ehnholm C, et al. Antibody against oxidized low density lipoprotein predicting myocardial infarction. Arch Intern Med. 1994;154:2605–2609
  18. Kistorp C, Galatius S, Gusstafsson F, Faber J, Corell P, Hildebrandt P. Prevalence and characteristics of diabetic patients in chronic heart failure population. Int J Cardiol. 2005;100:281–287
  19. George J, Harats D, Bakshi E, Adler Y, Levy Y, Gilburd B, et al. Anti-oxidized low density lipoprotein antibody determination as a predictor of restenosis following percutaneous transluminal coronary angioplasty. Immunol Lett. 1999;68:263–266
  20. Wright SP, Doughty RN, Pearl A, Gamble GD, Whalley GA, Walsh HJ, et al. Plasma amino- terminal pro-brain natriuretic peptide and accuracy of heart-failure diagnosis in primary care: a randomized, controlled trial. J Am Coll Cardiol. 2003;42:1793–1800
  21. Anand IS, Fisher LD, Chiang YT, Latini R, Masson S, Maggioni AP, et al. Val-HeFT Investigators. Changes in brain natriuretic peptide and norepinephrine over time and mortality and morbidity in the Valsartan Heart Failure Trial (Val-HeFT). Circulation. 2003;107:1278–1283
  22. George J, Wexler D, Roth A, Barak T, Sheps D, Keren G. Usefulness of anti-oxidized LDL antibody determination for assessment of clinical control in patients with heart failure. Eur J Heart Fail. 2006;8:58–62

 The authors have no conflicts of interest.

PII: S1071-9164(09)00171-7

doi: 10.1016/j.cardfail.2009.05.009

Journal of Cardiac Failure
Volume 15, Issue 9 , Pages 770-774 , November 2009

Article Tools